Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Clonidine × Clear all

Phase

Phase 3 3 Phase 2 3 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1 Neoplasms 1

Interventions

pembrolizumab 336 Cyclophosphamide 326 Carboplatin 265 Gemcitabine 239 Paclitaxel 234 Nivolumab 221 Cisplatin 206 Radiotherapy 183 Bevacizumab 172 Docetaxel 159 Dexamethasone 158 fludarabine 157 Rituximab 149 Capecitabine 138 Oxaliplatin 126 Lenalidomide 126 Fluorouracil 121 Temozolomide 115 Cytarabine 110 Etoposide 107 Irinotecan 106 Cetuximab 106 venetoclax 103 fludarabine phosphate 99 Doxorubicin 96 Injections 93 130-nm albumin-bound paclitaxel 93 Azacitidine 92 Pemetrexed 89 Ipilimumab 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡